Stockscreener 앱 받기
32.91
1.95%
0.63
시간 외 거래:
32.91
전일 마감가:
$32.28
열려 있는:
$33.18
하루 거래량:
9.42M
Relative Volume:
0.99
시가총액:
$38.33B
수익:
$17.41B
순이익/손실:
$1.43B
주가수익비율:
27.02
EPS:
1.2182
순현금흐름:
$1.00B
1주 성능:
-2.11%
1개월 성능:
-5.86%
6개월 성능:
+78.08%
1년 성능:
+109.75%
1일 변동 폭
$32.02
$33.30
1주일 범위
$31.71
$34.20
52주 변동 폭
$12.46
$37.34
테바 ADR Stock (TEVA) Company Profile
명칭
Teva Pharmaceutical Industries Ltd Adr
전화
972 (3) 914-8213
주소
TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV
Compare TEVA vs TAK, ZTS, HLN, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.91 | 37.59B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.22 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.96 | 53.16B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.47 | 47.25B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
UTHR
United Therapeutics Corp
|
490.21 | 21.85B | 3.13B | 1.27B | 1.12B | 26.39 |
테바 ADR Stock (TEVA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-12-05 | 개시 | Scotiabank | Sector Outperform |
| 2025-06-06 | 개시 | Goldman | Buy |
| 2025-05-28 | 개시 | Truist | Buy |
| 2025-05-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-07-10 | 업그레이드 | Argus | Hold → Buy |
| 2024-03-08 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2024-02-12 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-01-23 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-01-03 | 업그레이드 | Piper Sandler | Underweight → Neutral |
| 2023-12-18 | 개시 | HSBC Securities | Buy |
| 2023-11-27 | 업그레이드 | UBS | Neutral → Buy |
| 2023-07-06 | 업그레이드 | UBS | Sell → Neutral |
| 2023-05-25 | 개시 | Morgan Stanley | Equal-Weight |
| 2023-05-18 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-01-19 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-11-14 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-11-04 | 다운그레이드 | UBS | Neutral → Sell |
| 2022-10-21 | 재개 | Jefferies | Buy |
| 2022-08-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-06-14 | 재개 | UBS | Neutral |
| 2022-05-17 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-05-04 | 다운그레이드 | Piper Sandler | Neutral → Underweight |
| 2022-04-05 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2022-03-25 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2022-01-27 | 다운그레이드 | Argus | Buy → Hold |
| 2021-10-28 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-05-04 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2020-11-25 | 개시 | Oppenheimer | Perform |
| 2020-08-06 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2020-07-27 | 재개 | Goldman | Neutral |
| 2020-06-01 | 업그레이드 | SunTrust | Hold → Buy |
| 2020-04-24 | 재개 | Citigroup | Neutral |
| 2020-04-06 | 업그레이드 | UBS | Neutral → Buy |
| 2020-02-24 | 다운그레이드 | Edward Jones | Hold → Sell |
| 2019-11-12 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2019-10-17 | 업그레이드 | Gabelli & Co | Hold → Buy |
| 2019-08-07 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-07-19 | 개시 | Wolfe Research | Peer Perform |
| 2019-07-15 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2019-07-10 | 재개 | Credit Suisse | Neutral |
| 2019-07-05 | 업그레이드 | Argus | Hold → Buy |
| 2019-06-11 | 개시 | Barclays | Underweight |
| 2019-06-03 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-05-30 | 다운그레이드 | BofA/Merrill | Buy → Underperform |
| 2019-05-28 | 다운그레이드 | UBS | Buy → Neutral |
| 2019-03-20 | 개시 | SunTrust | Hold |
| 2019-03-07 | 재개 | UBS | Buy |
모두보기
테바 ADR 주식(TEVA)의 최신 뉴스
Billionaire Stanley Druckenmiller Dumped 2 of His Top Performers -- Teva and Taiwan Semiconductor -- and Made This Sector-Based ETF His Fund's New No. 2 Holding - The Motley Fool
A Look At Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Strong 1 Year Shareholder Returns - Sahm
Duvakitug IBD Data and TEV-749 Filing Might Change The Case For Investing In Teva (TEVA) - Sahm
Teva to Present at the Upcoming Investor Conferences in March - Sahm
J&J Stock Up 38% in 6 Months: Should You Buy, Sell or Hold? - Finviz
Where is Teva Pharmaceutical Industries Limited (TEVA) Headed? - Finviz
Teva’s Olanzapine And Duvakitug Updates Test Valuation Gap Narrative - Sahm
Corcept's Q4 Earnings and Revenues Fall Short of Estimates - Finviz
Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Its Strong Recent Share Price Momentum - Sahm
Truist Boosts Teva (TEVA) Stock Target Amid Pipeline Growth Opportunities - Finviz
U.S. Food and Drug Administration (FDA) Accepts Teva’s New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults - Sahm
Teva And Sanofi Duvakitug Data Support IBD Pipeline And Growth Story - Sahm
Goldman Sachs See Teva Pharmaceutical Industries Limited (TEVA) Driving Double-Digit Earnings Growth Through 2026 - Finviz
Teva Pharmaceutical Industries Ltd (TEVA) Stock Price, Trades & News - GuruFocus
13 Analysts Have This To Say About Teva Pharmaceutical Indus - Sahm
Should You Invest in Teva Pharmaceutical (TEVA), Here's What the Street Has to Say - Finviz
Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease - Sahm
Teva (TEVA) Is Down 5.2% After Returning To Profitability On Innovation-Led Revenue Shift – What’s Changed - Sahm
Teva Pharmaceutical Industries (NYSE:TEVA) Valuation In Focus Amid Momentum - Kalkine Media
Here's What Analysts Are Saying About Teva Pharmaceutical (TEVA) Post Earnings - Finviz
Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Recent Share Price Momentum And Biosimilar Growth Hopes - Sahm
A Look Into Teva Pharmaceutical Indus Inc's Price Over Earnings - Sahm
Barclays Raises Teva Pharmaceutical (TEVA) PT to $38 Following Strong Q4 Earnings Beat - Finviz
Teva Canada Announces Approval of Expanded Indication of [Pr]AJOVY® (fremanezumab solution for subcutaneous injection), the First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine - Sahm
Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory - Finviz
Teva Canada Mayzent Deal Supports Neuroscience Focus And Valuation Debate - Sahm
FedEx Upgraded, Costco Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Earnings call transcript: Teva Q4 2025 earnings beat expectations, stock rises - Investing.com
Assessing Teva Pharmaceutical Industries’ Valuation After Strong 2025 Earnings And Analyst Upgrades - Sahm
Teva (TEVA) Is Up 7.1% After 2025 Earnings Highlight Branded-Drugs Momentum And Pipeline Progress - Sahm
Analysts See Pipeline Catalysts Driving Teva Pharmaceutical Industries Limited (TEVA)'s 2026 Growth Despite Revenue Headwinds - Finviz
Jim Cramer Highlights Teva Pharmaceutical's Growth Under CEO Richard Francis - Finviz
Is Teva Pharmaceutical Industries (TEVA) Still Attractive After A 92% One-Year Share Price Surge - Sahm
Teva Pharmaceutical Industries (NYSE:TEVA) Reaches New 12-Month High Following Earnings Beat - Defense World
Teva Balances Huntington’s Disease Outreach With Branded Drug Transformation - Sahm
TEVA's Q4 Earnings Beat, Branded Drugs Drive Revenue Growth - Finviz
What Makes Teva Pharmaceuticals (TEVA) a Successful Brand? - Finviz
Teva Pharma stock hits 52-week high at 33.42 USD By Investing.com - Investing.com Nigeria
Teva Pharma stock hits 52-week high at 33.42 USD - Investing.com
Teva Pharmaceutical Industries (NYSE:TEVA) Earnings Margin Recovery Challenges High P/E Valuation Narrative - Sahm
Teva To See Generics Loss From Revlimid in 2026, but Innovative Portfolio Drives Margin Expansion - morningstar.com
Teva's Flagship Drugs Hit $1 Billion Milestone, Raises Confidence In 2026 Outlook - Sahm
Earnings call transcript: Teva beats Q4 2025 EPS forecast, stock dips - Investing.com
Teva Earnings: Valuation Raised on Solid End to Year, as Innovative Engine Keeps on Firing - Morningstar
Assessing Teva (TEVA) Valuation As Guidance Driven Momentum Lifts Long Term Profit Expectations - Sahm
The Truth About Teva Pharmaceutical (ADR): Why Everyone Is Suddenly Watching This Stock - AD HOC NEWS
Should You Buy, Sell or Hold J&J Stock Ahead of Q4 Results? - Finviz
Sodium Chloride Injections Market, Global Forecast 2026-2032 - GlobeNewswire Inc.
테바 ADR (TEVA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.32%
0.02%
자본화:
|
볼륨(24시간):